Patents by Inventor Denis Labrecque
Denis Labrecque has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150216861Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.Type: ApplicationFiled: April 13, 2015Publication date: August 6, 2015Inventors: James Arnold, Andrew Todd Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
-
Patent number: 9029381Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.Type: GrantFiled: November 21, 2011Date of Patent: May 12, 2015Assignee: Astrazeneca ABInventors: James Arnold, Todd Andrew Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
-
Patent number: 8168668Abstract: The present invention relates to new compounds or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.Type: GrantFiled: October 14, 2009Date of Patent: May 1, 2012Assignee: AstraZeneca ABInventors: Yevgeni Besidski, Martin Nylof, Inger Kers, Karin Skogholm, Shawn Johnstone, Paul Jones, Denis Labrecque, Andrew Griffin
-
Publication number: 20120065193Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.Type: ApplicationFiled: November 21, 2011Publication date: March 15, 2012Inventors: James Arnold, Andrew Todd Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
-
Patent number: 8093402Abstract: Provided herein are compounds in accord with Formula I: that are useful in the treatment of pain.Type: GrantFiled: February 8, 2011Date of Patent: January 10, 2012Assignee: AstraZeneca ABInventors: William Brown, Shawn Johnstone, Denis Labrecque
-
Patent number: 8063215Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.Type: GrantFiled: August 21, 2008Date of Patent: November 22, 2011Assignee: AstraZeneca ABInventors: James Arnold, Todd Andrew Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
-
Patent number: 7968595Abstract: The present invention is directed to a substituted 4H-chromene represented by the Formula 1R, substantially free from the corresponding (S)-stereoisomer: The present invention also relates to the discovery that compound 1R, substantially free from the corresponding (S)-stereoisomer, is an activator of caspases and inducer of apoptosis, as well as an antivascular agent. Therefore, compound 1R, substantially free from the corresponding (S)-stereoisomer, can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. Compound 1R, substantially free from the corresponding (S)-stereoisomer, also can be used for the treatment of diseases due to overgrowth of vasculature, such as solid tumors and ocular neovascularization.Type: GrantFiled: July 6, 2007Date of Patent: June 28, 2011Assignee: Cytovia, Inc.Inventors: Sui Xiong Cai, John A. Drewe, Shailaja Kasibhatla, William D. Kemnitzer, Ben Y. Tseng, Charles Blais, Denis Labrecque, Henriette Gourdeau
-
Publication number: 20110137045Abstract: Provided herein are compounds in accord with Formula I: that are useful in the treatment of pain.Type: ApplicationFiled: February 8, 2011Publication date: June 9, 2011Applicant: AstraZeneca ABInventors: William Brown, Shawn Johnstone, Denis Labrecque
-
Patent number: 7906654Abstract: Provided herein are compounds in accord with Formula I: that are useful in the treatment of pain.Type: GrantFiled: August 9, 2007Date of Patent: March 15, 2011Assignee: AstraZeneca ABInventors: William Brown, Shawn Johnstone, Denis Labrecque
-
Publication number: 20100286202Abstract: The present invention relates to new compounds or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.Type: ApplicationFiled: October 14, 2009Publication date: November 11, 2010Applicant: AstraZeneca ABInventors: Yevgeni Besidski, Martin Nylöf, Inger Kers, Karin Skogholm, Shawn Johnstone, Paul Jones, Denis Labrecque, Andrew Griffin
-
Patent number: 7618993Abstract: The present invention relates to new compounds or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.Type: GrantFiled: December 21, 2006Date of Patent: November 17, 2009Assignee: AstraZeneca ABInventors: Yevgeni Besidski, Martin Nylöf, Inger Kers, Karin Skogholm, Shawn Johnstone, Paul Jones, Denis Labrecque, Andrew Griffin
-
Publication number: 20090076020Abstract: Disclosed herein is at least one cyclopropyl amide derivative, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative disclosed herein, and at least one method of using at least one cyclopropyl amide derivative disclosed herein for treating at least one histamine H3 receptor associated condition therewith.Type: ApplicationFiled: August 21, 2008Publication date: March 19, 2009Applicant: ASTRAZENECA ABInventors: James Arnold, Todd Andrew Brugel, Scott Throner, Steven Wesolowski, Phil Edwards, Andrew Griffin, Thierry Groblewski, Denis Labrecque
-
Publication number: 20080221188Abstract: Provided herein are compounds in accord with Formula I: that are useful in the treatment of pain.Type: ApplicationFiled: August 9, 2007Publication date: September 11, 2008Applicant: AstraZeneca R&D SodertaljeInventors: William Brown, Shawn Johnstone, Denis Labrecque
-
Publication number: 20080114041Abstract: The present invention relates to new compounds of formula I, wherein R1 to R4 are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.Type: ApplicationFiled: December 19, 2005Publication date: May 15, 2008Applicant: AstraZeneca ABInventors: William Brown, Shawn Johnstone, Paul Jones, Denis Labrecque, Mickael Maudet, Christopher Walpole
-
Publication number: 20080108676Abstract: The present invention relates to new compounds of formula I, (I) wherein R1 to R4, m, n and p, are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to a new intermediate used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.Type: ApplicationFiled: December 19, 2005Publication date: May 8, 2008Applicant: New BenzothiazolecarboxamidesInventors: William Brown, Andrew Griffin, Shawn Johnstone, Denis Labrecque, Alexander Munro, Sandrine Pache, Christopher Walpole
-
Publication number: 20080085328Abstract: The present invention is directed to a substituted 4H-chromene represented by the Formula 1R, substantially free from the corresponding (S)-stereoisomer: The present invention also relates to the discovery that compound 1R, substantially free from the corresponding (S)-stereoisomer, is an activator of caspases and inducer of apoptosis, as well as an antivascular agent. Therefore, compound 1R, substantially free from the corresponding (S)-stereoisomer, can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. Compound 1R, substantially free from the corresponding (S)-stereoisomer, also can be used for the treatment of diseases due to overgrowth of vasculature, such as solid tumors and ocular neovascularization.Type: ApplicationFiled: July 6, 2007Publication date: April 10, 2008Inventors: Sui Xiong Cai, John A. Drewe, Shailaja Kasibhatla, William E. Kemnitzer, Ben Y. Tseng, Charles Blais, Denis Labrecque, Henriette Gourdeau
-
Publication number: 20080070946Abstract: The present invention relates to new compounds, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.Type: ApplicationFiled: October 5, 2005Publication date: March 20, 2008Applicant: AstraZeneca ABInventors: Yevgeni Besidski, William Brown, Magali Harter, Yin Hu, Shawn Johnstone, Paul Jones, Denis Labrecque, Alexander Munro, Christopher Walpole
-
Publication number: 20060223868Abstract: Compounds of formula I, wherein R1, n, R3, R4, R7, R8 and P are as defined in the specification, salts, solvates or solvated salts thereof, processes for their preparation, new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and the use of said compounds in therapy.Type: ApplicationFiled: April 26, 2004Publication date: October 5, 2006Applicant: AstraZeneca ABInventors: Yevgeni Besidski, William Brown, Shawn Johnstone, Denis Labrecque, Alexander Munro, Didier Rotticci, Christopher Walpole, Ronald Zemribo, Andreas Petersson
-
Patent number: 6960594Abstract: A novel compound which inhibits certain integrins, particularly ?v integrins. Additionally, the novel compound may be used in a method of treating tumors or cancer which comprises administering a pharmaceutically effective amount of the compound to a patient. Additionally, the novel compound may be used in a method of inhibiting angiogensis. Finally, a method of producing the novel compound is disclosed.Type: GrantFiled: January 16, 2002Date of Patent: November 1, 2005Assignee: Shire BioChem Inc.Inventors: Denis Labrecque, Serge Lamothe, Marc Courchesne, Laval Chan, Giorgio Attardo, Karen Meerovitch
-
Patent number: 6857330Abstract: A scanner assembly for dovetail inspection of the wheels of a turbine rotor includes a series of circumferentially pivotally connected links: a motor link, transmission links, an encoder link, an adjustable link, free links and a base link mounting a transducer. The motor link mounts a motor for driving rollers on the transmission links and rotating the scanner assembly about the rotor shaft. The encoder link mounts an encoder for determining the circumferential position of the transducer about the shaft. The adjustable link enables the assembly to be tightened or loosened about the rotor shaft. The free links and base link complete the circular scanner assembly about the shaft. A single scan for a full 360° investigates the plurality of hooks on the side of the wheel opposite the transducer.Type: GrantFiled: May 31, 2002Date of Patent: February 22, 2005Assignee: General Electric CompanyInventors: Thomas Francis Murphy, Robert Martin Roney, Jr., Robert L'Heureux, Denis Labrecque